Simultaneous determination of ACE activity with 2 substrates provides information on the status of somatic ACE and allows detection of inhibitors in human blood

Journal of Cardiovascular Pharmacology

Volumn 52, Issue 1, 2008, Pages 90-103

  Danilov, Sergei M ^a   Balyasnikova, Irina V ^a   Albrecht, Ronald F ^a   Kost, Olga A ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

ACE inhibitors; Angiotensin converting enzyme; Blood; Kinetic analysis; Urine

Indexed keywords

BENZYLOXYCARBONYLPHENYLALANYLHISTIDYLLEUCINE; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; HIPPURYLHISTIDYLLEUCINE; LISINOPRIL; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; HIPPURYL-HISTIDYL-LEUCINE; N CARBOBENZOXY PHENYLALANYL HISTIDYL LEUCINE; N-CARBOBENZOXY-PHENYLALANYL-HISTIDYL-LEUCINE; OLIGOPEPTIDE;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME SUBSTRATE; HUMAN; HYDROLYSIS; PRIORITY JOURNAL; BLOOD; ENZYME SPECIFICITY; KINETICS; METABOLISM; PROTEIN TERTIARY STRUCTURE; URINE; WESTERN BLOTTING;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOTTING, WESTERN; HUMANS; KINETICS; OLIGOPEPTIDES; PROTEIN STRUCTURE, TERTIARY; SUBSTRATE SPECIFICITY;

EID: 55949129177     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31817fd3bc     Document Type: Article

References (63)

1. Ehlers MRW, Riordan JF. Angiotensin-converting enzyme: New concepts concerning its biological role. Biochemistry. 1989;28:5311-5318.
2. Skidgel RA, Erdos EG. Biochemistry of angiotensin I- converting enzyme. In: Robertson JIS, Nichols MG, eds. The Renin-Angiotensin System. New York: Glower Medical Publishing, 1993:10.1-10.10.
3. Dzau VJ, Bernstein K, Celermajer D, et al. The relevance of tissue angiotensin-converting enzyme: Manifestations in mechanistic and endpoint data. Am J Cardiol. 2001;88:1L-20L.
4. Acharya KR, Sturrock ED, Riordan JF, et al. ACE revisited: A new target for structure-based drug design. Nat Rev Drug Discov. 2003;2:891-902.
5. Corvol P, Eyries M, Soubrier F. Peptidyl-dipeptidase A/Angiotensin Iconverting enzyme. In: Barret AA, Rawlings ND, Woessner JF, eds. Handbook of Proteolytic Enzymes. New York: Elsevier Academic Press, 2004:332-349.
6. Danilov SM, Franke FE, Erdos EG. Angiotensin-converting enzyme (CD143). In: Kishimoto T, Kikutani H, von dem Borne AEGK, et al, eds. Leucocyte Typing VI: White Cell Differentiation Antigen. New York: Garland Publishing, 1997:746-749.
7. Franke FE, Metzger R, Bohle R.M, et al. Angiotensin I-converting enzyme (CD 143) on endothelial cells in normal and in pathological conditions. In: Kishimoto T, Kikutani H, von dem Borne AEGK, et al, eds. Leucocyte Typing VI: White Cell Differentiation Antigen. New York: Garland Publishing, 1997:749-751.
8. Wei L, Alhenc-Gelas F, Soubrier F, et al. Expression and characterization of recombinant human angiotensin I-converting enzyme. Evidence for a C-terminal transmembrane anchor and for a proteolytic processing of the secreted recombinant and plasma enzymes. J Biol Chem. 1991;266: 5540-5546.
9. Ramchandran R, Kasturi S, Douglas JG, et al. Metalloprotease-mediated cleavage secretion of pulmonary ACE by vascular endothelial and kidney epithelial cells. Am J Physiol. 1996;271:H744-H751.
10. Woodman ZL, Oppong SY, Cook S, et al. Shedding of somatic angiotensinconverting enzyme (ACE) is inefficient compared with testis ACE despite cleavage at identical stalk sites. Biochem J. 2000;347:711-718.
11. Ching SF, Hayes LW, Slakey LL. Angiotensin-converting enzyme in cultured endothelial cells. Synthesis, degradation and transfer to culture medium. Arteriosclerosis. 1983;3:581-588.
12. Soubrier F, Alhenc-Gelas F, Hubert C, et al. Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Natl Acad Sci USA. 1988;85:9386-9390.
13. Wei L, Alhenc-Gelas F, Corvol P, et al. The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J Biol Chem. 1991;266:9002-9008.
14. Jaspard E, Wei L, Alhenc-Gelas F. Differences in properties and enzymatic specificities between the two active sites of human angiotensin I-converting enzyme: Studies with bradykinin and other natural peptides. J Biol Chem. 1993;268:9496-9503.
15. Georgiadis D, Beau F, Czarny B, et al. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: Insights from selective inhibitors. Circ Res. 2003;93:148-154.
16. Skirgello OE, Binevski PV, Pozdnev VF, et al. Kinetic probes for interdomain cooperation in human somatic angiotensin-converting enzyme. Biochem J. 2005;391:641-647.
17. Perich RB, Jackson B, Rogerson F, et al. Two binding sites on angiotensinconverting enzyme: Evidence from radioligand binding studies. Mol Pharmacol. 1992;42:286-293.
18. Dive V, Cotton J, Yiotakis A, et al. RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites. Proc Natl Acad Sci USA. 1999;96:4330-4335.
19. Binevski PV, Sizova EA, Pozdnev VF, et al. Evidence for the negative cooperativity of the two active sites within bovine somatic angiotensinconverting enzyme. FEBS Lett. 2003;550:84-88.
20. Kaiser G, Ackermann R, Dieterle W, et al. Determination of a new angiotensin converting enzyme inhibitor and its active metabolite in plasma and urine by gas chromatography-mass spectrometry. J Chromatogr. 1987;419:123-133.
21. Ezan E, Morge X, Lelievre E, et al. Enzyme immunoassays for a new angiotensin-converting enzyme inhibitor, zabicipril, and its active metabolite in human plasma: Application to pharmacokinetic studies. Ther Drug Monit. 1993;15:448-454.
22. Hillaert S, Van den Bossche W. The quantitative determination of several inhibitors of angiotensin-converting enzyme by CE. J Pharm Biomed Anal. 2001;25:775-783.
23. Danilov S, Jaspard E, Churakova T, et al. Structure-function analysis of angiotensin I-converting enzyme using monoclonal antibodies. J Biol Chem. 1994;269:26806-26814.
24. Skirgello OE, Balyasnikova IV, Binevski PV, et al. Inhibitory antibodies to human angiotensin-converting enzyme: Fine epitope mapping and mechanism of action. Biochemistry. 2006;45:4831-4847.
25. Metzger R, Bohle R-M, Kerkman L, et al. Distribution of angiotensin I-converting enzyme (CD 143) in the normal human kidney and in nonneoplastic kidney diseases. Kidney Int. 1999;56:1442-1454.
26. Balyasnikova IV, Metzger R, Sun Z-L, et al. Development and characterization of rat monoclonal antibodies to denatured mouse angiotensin-converting enzyme. Tissue Antigens. 2005;65:240-251.
27. Bull HG, Thornberry NA, Cordes EH. Purification of angiotensinconverting enzyme from rabbit lung and human plasma by affinity chromatography. J Biol Chem. 1985;260:2963-2972.
28. Hooper NM, Turner AJ. Isolation of two differentially glycosylated forms of peptidyl-dipeptidase A (angiotensin-converting enzyme) from pig brain: A re-evaluation of their role in neuropeptide metabolism. Biochem J. 1987;241:625-633.
29. Balyasnikova IV, Gavriljuk VD, McDonald TD, et al. Antibody-mediated lung endothelium targeting: In vitro model using a cell line expressing angiotensin-converting enzyme. Tumor Targeting. 1999;4:70-83.
30. Balyasnikova IV, Metzger R, Franke FE, et al. Monoclonal antibodies to denatured human ACE (CD143): Broad species specificity, reactivity on paraffin-section, and detection of subtle conformational changes in the C-terminal domain of ACE. Tissue Antigens. 2003;61:49-62.
31. Ehlers MRW, Chen Y-N, Riordan JF. Spontaneous solubilization of membrane-bound human testis angiotensin-converting enzyme expressed in Chinese hamster ovary cells. Proc Natl Acad Sci USA. 1991;88:1009-1013.
32. Friedland J, Silverstein E. A sensitive fluorometric assay for serum angiotensin-converting enzyme. Am J Clin Path. 1976;66:416-424.
33. Piquilloud Y, Reinharz A, Roth, M. Studies on the angiotensin-converting enzyme with different substrates. Biochim Biophys Acta. 1970;206:136-142.
34. Williams TA, Danilov SM, Alhenc-Gelas F, et al. A study of chimeras constructed with the two domains of angiotensin I-converting enzyme. Biochem Pharmacol. 1996;51:11-14.
35. Marcic B, Deddish PA, Jackman HL, et al. Effects of the N-terminal sequence of ACE on the properties of its C-domain. Hypertension. 2000; 36:116-21.
36. Voronov S, Zueva N, Orlov V, et al. Temperature-induced selective death of the C-domain within angiotensin-converting enzyme molecule. FEBS Lett. 2002;522:77-82.
37. Deddish PA, Wang J, Michel B, et al. Naturally occurring active N-domain of human angiotensin I-converting enzyme. Proc Natl Acad Sci USA. 1994;91:7807-7811.
38. Costa RH, Casarini DE, Plavnik FL, et al. Angiotensin converting-like enzymes from urine of untreated renovascular hypertensive and normal patients: Purification and characterization. Immunopharmacology. 2000; 46:237-246.
39. Hattori MA, Del Ben GL, Carmona AK, et al. Angiotensin I-converting enzyme isoforms (high and low molecular weight) in urine of premature and full-term infants. Hypertension. 2000;35:1284-1290.
40. Casarini DE, Plavinik FL, Zanella MT, et al. Angiotensin converting enzyme from human urine of mild hypertensive untreated patients resemble the N terminal fragment of human angiotensin I-converting enzyme. Int J Biochem Cell Biol. 2001;33:75-85.
41. Marques GD, Quinto BM, Plavinik FL, et al. N-domain angiotensin I-converting enzyme with 80 kDa as a possible genetic marker of hypertension. Hypertension. 2003;42:693-701.
42. Deddish PA, Wang LX, Jackman HL, et al. Single-domain angiotensin I converting enzyme (kininase II): Characterization and properties. J Pharmacol Exp Ther. 1996;279:1582-1589.
43. Sturrock ED, Danilov SM, Riordan JF. Limited proteolysis of human kidney angiotensin-converting enzyme and generation of catalytically active N- and C-terminal domains. Biochem Biophys Res Commun. 1997; 236:16-19.
44. Wei L, Clauser E, Alhenc-Gelas F, et al. The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J Biol Chem. 1992;267:13398-13405.
45. Michaud A, Williams TA, Chauvet MT, et al. Substrate dependence of angiotensin I-converting enzyme inhibition: Captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I. Mol Pharmacol. 1997;51:1070-1076.
46. Grinshtein SV, Binevski PV, Gomazkov OA, et al. Inhibitor analysis of angiotensin I-converting and kinin-degrading activities of bovine lung and testicular angiotensin-converting enzyme. Biochemistry (Mosc). 1999;64: 938-944.
47. Gu Q, Chen X, Zhong D, et al. Simultaneous determination of enalapril and enalaprilat in human plasma by liquid chromatography - Tandem mass spectrometry. J Chromatography B. 2004;813:337-342.
48. Cotton J,Hayashi MAF Cuniasse P, et al. Selective inhibition of the C-domain of angiotensin I converting enzyme by bradykinin potentiating peptides. Biochemistry. 2002;41:6065-6071.
49. Lieberman J, Sastre A. An angiotensin-converting enzyme (ACE) inhibitor in human serum. Increased sensitivity of the serum ACE assay for detecting active sarcoidosis. Chest. 1986;90:869-875.
50. Ryan JW, Martin LC, Chung A, et al. Mammalian inhibitors of angiotensin converting enzyme (kininase II). Adv Exp Med Biol. 1979; 120B:599-606.
51. Ryan JW, Oza NB, Martin LC, et al. Components of the kallikrein-kinin system in urine. Adv Exp Med Biol. 1979 ;120A:313-323.
52. Ikemoto F, Song GB, Tominaga M, et al. Endogenous inhibitor of angiotensin converting enzyme in the rat heart. Biochem Biophys Res Commun. 1989;159:1093-1099.
53. Brecher AS, Thevananther S, Wilson S. Observation of high and low molecular weight inhibitors of angiotensin-converting enzyme in rat lung. Arch Int Pharmacodyn Ther. 1996;331:301-312.
54. Araujo MC, Melo RL, Cesari MH, et al. Peptidase specificity characterization of C- and N-terminal catalytic sites of angiotensin I-converting enzyme. Biochemistry. 2000;39:8519-8525.
55. Bersanetti PA, Andrade MC, Casarini DE, et al. Positional-scanning combinatorial libraries of fluorescence resonance energy transfer peptides for defining substrate specificity of the angiotensin I-converting enzyme and development of selective C-domain substrates. Biochemistry. 2004; 43:15729-15736.
56. Balyasnikova IV, Metzger R, Sun Z-L, et al. Monoclonal antibodies 1B3 and 5C8 as probes for monitoring the nativity of C-terminal end of soluble angiotensin-converting enzyme (ACE). Hybridoma. 2005;24:14-25.
57. Ehlers MR, Riordan JF. Angiotensin-converting enzyme: Zinc- and inhibitor-binding stoichiometries of the somatic and testis isozymes. Biochemistry. 1991;30:7118-7126.
58. Kohlstedt K, Gershome C, Friedrich M, et al. Angiotensin converting enzyme (ACE) dimerization is the initial step in the ACE inhibitorinduced ACE signaling cascade in endothelial cells. Mol Pharm. 2006;69: 1725-1732.
59. Balyasnikova IV, Skirgello OE, Binevski PV, et al. Monoclonal antibodies 1G12 and 6A12 to the N-domain of human angiotensin-converting enzyme:fine epitope mapping and antibody-based detection of ACE inhibitors in the human blood. J Proteome Res. 2007;6:1580-1594.
60. Hazato T, Kase R. Isolation of angiotensin-converting enzyme inhibitor from porcine plasma. Biochim Biophys Res Commun. 1986,139:52-55.
61. Murray BA, Fitzgerald RJ. Angiotensin converting enzyme inhibitory peptides derived from food proteins: Biochemistry, bioactivity and production. Curr Pharm Des. 2007,13:773-791.
62. Janitha PK, Wanasundara PD, Ross ARS, et al. Peptides with angiotensin I-converting enzyme (ACE) inhibitory activity from defibrinated, hydrolysed bovine plasma. J Agric Food Chem. 2002,50:6981-6988.
63. Nesterovitch A, Hogarth K, Berestetskaya Y, et al. A novel point mutation of angiotensin I-converting enzyme (Trp1197Stop) is associated with a dramatic increase in serum ACE in a patient with asthma. Am J Resp Crit Care Med. 2007;175:A462.